Technology
Health
Pharmaceutical

Intersect ENT

$33.39
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (0.45%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Intersect ENT and other stocks, options, ETFs, and crypto commission-free!

About

Intersect ENT, Inc. Common Stock, also called Intersect ENT, is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Read More The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.

Employees
393
Headquarters
Menlo Park, California
Founded
2003
Market Cap
1.02B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
322.26K
High Today
$34.15
Low Today
$33.01
Open Price
$33.01
Volume
61.14K
52 Week High
$42.95
52 Week Low
$25.09

Collections

Technology
Health
Pharmaceutical
2014 IPO
US
North America
Female CEOs

News

Yahoo FinanceMar 7

Did Intersect ENT’s Share Price Deserve to Gain 89%?

By buying an index fund, investors can approximate the average market return. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just take a look at Intersect ENT, Inc. (NASDAQ:XENT), which is up 89%, over three years, soundly beating the market return of 40% (not including dividends). See our latest analysis for Intersect ENT Intersect ENT isn’t currently profitable, so most analysts would look to revenue growth to get an idea of how fast t...

15
Simply Wall StMar 2

Can You Imagine How Intersect ENT’s Shareholders Feel About The 81% Share Price Increase?

By buying an index fund, you can roughly match the market return with ease. But if you buy good businesses at attractive prices, your portfolio returns could exceed the average market return. Just take a look at Intersect ENT, Inc. (NASDAQ:XENT), which is up 81%, over three years, soundly beating the market return of 40% (not including dividends). View our latest analysis for Intersect ENT Intersect ENT isn’t currently profitable, so most analysts would look to revenue growth to get an idea of how fast th...

0
Yahoo FinanceMar 1

Edited Transcript of XENT earnings conference call or presentation 25-Feb-19 9:30pm GMT

Q4 2018 Intersect Ent Inc Earnings Call Menlo Park Feb 27, 2019 (Thomson StreetEvents) -- Edited Transcript of Intersect ENT Inc earnings conference call or presentation Monday, February 25, 2019 at 9:30:00pm GMT TEXT version of Transcript Scroll to continue with content Ad ================================================================================ Corporate Participants ================================================================================ * Jeryl L. Hilleman Intersect ENT, Inc. - CF...

2

Earnings

-$0.27
-$0.21
-$0.14
-$0.08
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected Apr 30, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.